AbbVie Submits Biologics License Application to FDA for Etentamig in Relapsed/Refractory Multiple Myeloma

AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager. The intravenous treatment is proposed for adults with relapsed or refractory multiple myeloma, following positive results from the Phase 3 CERVINO study which showed significant improvements in overall response rate and progression-free survival.